BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 01, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Velcade bortezomib regulatory update

The U.K.'s NICE issued final guidance recommending the use of thalidomide from Celgene Corp. (NASDAQ:CELG, Summit, N.J.) and Velcade bortezomib from Johnson & Johnson for first-line multiple myeloma (MM), but said Velcade should only be used when patients are unable to receive the more cost-effective...

Read the full 213 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >